bis-choline tetrathiomolybdate

Small moleculeexperimental

Tiomolibdic acid is a chelating agent under investigation for the treatment of cancer and of Wilson's disease, a rare and potentially fatal disease in which the body cannot regulate copper. It is developed by Wilson Therapeutics and used in form of the salt bis-choline tetrathiomolybdate. — Wikipedia

Clinical trial activity

18 trials · 15 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jan 1, 1994 (NCT00004339)

Timeline

1990s

Jan 1, 1994
Earliest Phase 3 Sponsor(trial)

2000s

Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
Jan 1, 2003
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

CopperCHELATING AGENT
Copper chelating agent

Chemistry & pharmacology

Oral

Parenteral

Topical

Sources

WikipediaTiomolibdic acid ↗
WikipediaBis-choline tetrathiomolybdate ↗

Also known as

ammonium tetrathiomolybdate
ammonium tetrathiomolybdate
ammonium tetrathiomolybdate
atn-224
atn-224
atn-224
atn-224
molybdate(2-), tetrathioxo-, (t-4)-
tetrathiomolybdate
tetrathiomolybdate
tetrathiomolybdate
tetrathiomolybdate bis-choline salt
tetrathiomolybdate, dipotassium salt
tetrathiomolybdate, disodium salt
thiomolybdate
tiomolibdate ion
tiomolibdate ion
ttm cpd

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06134375	Phase 1/Phase 2 (Phase 2)	Mar 31, 2024	Dartmouth University, Department of Defense, National Cancer Institute (NCI)
NCT04422431	Phase 2	Jun 30, 2020	Alexion
NCT05319912	Phase 1	Apr 7, 2014	Alexion
NCT01837329	Phase 1	Nov 1, 2013	University of Rochester
NCT00674557	Phase 2	Jun 1, 2008	Cancer Research UK, University of Oxford
NCT00560495	Phase 1	May 1, 2007	National Cancer Institute (NCI), State University of New York, Buffalo
NCT00405574	Phase 2	Nov 1, 2006	Attenuon, Prostate Cancer Clinical Trials Consortium
NCT00383851	Phase 2	Sep 1, 2006	Attenuon
NCT00352742	Phase 1/Phase 2 (Phase 2)	Jun 1, 2006	Attenuon
NCT00805805	Phase 3	Apr 1, 2006	Food and Drug Administration, University of Michigan
NCT00113542	Phase 2	Jun 1, 2004	University of Michigan
NCT00195091	Phase 2	Dec 1, 2003	Cornell University
NCT00189176	Phase 1/Phase 2 (Phase 2)	Mar 1, 2003	Coalition for Pulmonary Fibrosis, University of Michigan
NCT00176800	Phase 2	Nov 1, 2001	University of Michigan
NCT00150995	Phase 2	May 1, 2001	University of Michigan
NCT00176774	Phase 2	Feb 1, 2001	University of Michigan
NCT00006332	Phase 2	Oct 4, 2000	National Center for Research Resources (NCRR)
NCT00004339	Phase 3	Jan 1, 1994	National Center for Research Resources (NCRR), University of Michigan

Showing 18 of 18 trials

Page 1 / 1

Organizations

Research & Development (15)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
University of Michigan	Academic/Hospital	7	6	2	1994
Attenuon	For profit	3	3	1	2006
Alexion	For profit	2	2	2	2014
National Cancer Institute (NCI)	Government	2	0	2	2007
National Center for Research Resources (NCRR)	Government	2	2	2	1994
Cancer Research UK	Academic/Hospital	1	1	1	2008
Coalition for Pulmonary Fibrosis	Academic/Hospital	1	0	1	2003
Cornell University	Academic/Hospital	1	1	1	2003
Dartmouth University	Academic/Hospital	1	1	1	2024
Department of Defense	Government	1	0	1	2024
Food and Drug Administration	Government	1	0	1	2006
Prostate Cancer Clinical Trials Consortium	Academic/Hospital	1	0	1	2006
State University of New York, Buffalo	Academic/Hospital	1	1	1	2007
University of Oxford	Academic/Hospital	1	0	1	2008
University of Rochester	Academic/Hospital	1	1	1	2013

15 organizations

Page 1 / 1